Less-Intensive Leukemia Regimen Outperforms Standard Chemo

A randomized phase 2 trial found azacitidine and venetoclax, a less-intensive regimen, more than doubled event-free survival compared to standard induction chemotherapy for fit patients with high-risk acute myeloid leukemia.

This Wire brief sits within Fusion42's coverage of Biotech.